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feasible in 40 (83%) pts.
TIE TEE PI. CATH
MIG(mmH9) 55.9* 62.4
mGlmmHg) 41.8* 45.8
LVOT area Icm2) 39 4.0'
AVAlcm2) 0.91* 0.90*' 0.88* 0.89
Correlations between Doppler- and CATH-derived gradients were excellent
either simultaneously or not (MIG = 0.96, SEE = 6, p < 0.001; mG, r = 0.96,
SEE = 4, P < 0.001; AVA, r 0.92, SEE 0.18, P < 0.0011. PL-AVA and CATH
correlated less closely (r 0.78, SEE 0.22, P < 0.001). In conclusion: 1) TEE-
LVOT is measurable in 100% of AS pts and can be accurately used as an
alternative when TIE-LVOT is suboptimal; 2) AVA-PL is measurable in 83%
of AS pts and less accurate than the CE; and 3) Doppler-derived gradients
do not need to be done simultaneously to accurately reflect CATH as long
as Doppler is performed in dose temporal relation and by an experienced
sonographer.
*, comparison with CATH p < 0.001, t, comparison with TIE p < 0.001)
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Prognostic Value of Ultra-Low Frequency Heart
Rate Variability in Chronic Aortic Regurgitation
Lisa A. Freed, Kenneth M. Stein, Jeffrey S. Borer, Clare Hochreiter, PhylliS Supino,
Richard B. Devereux, Paul Kligfield. The New York Hospital- Cornell Medical Cenrer,
New York, NY
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(1) For any anatomic area, Cc was larger for the longer tapered dome,
which allows more gradual flow convergence proximal to the limiting ori-
fice (less distal contraction). (2) For each funnel shape, Cc increased with
increasing orifice to proximal funnel size (more tube-like). Conclusions: Cc,
which can alter net head loss, is importantly affected by the variations in
leaflet geometry seen in patients. Echo stereolithography can allow us to
address such uniquely 3D questions.
Effects of Facilitation on Human AV Nodal Fast
and Slow Pathways
Sotalol in the Treatment of Resistant
Supraventricular Arrhythmias
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University ofArizona, Tucson, AZ
D,L-Sotalol is newly approved for the treatment of life-threatening ventricu-
lar arrhythmias. Several small studies suggest that d,l-sotalol is also useful in
the management of supraventricular arrhythmias (SVA). To determine the ef-
ficacy and safety of d,l-sotalol in the treatment of resistant SVA, data from the
d,l-sota/o/ compassionate use database were examined. One hundred fifty-
four patients, 53 ± 15.3 years of age with SVA, who had failed an average of
5.2 ± 1.8 antiarrhythmics, were enrolled. Ninety-four (61 %) patients had AF,
22 (14%) WPW, 20 (13%) SVT, 12 (8%) AFL and 6 (4%) AVNRI Forty-three
patients (28%1 had d,l-sotalol discontinued during the acute phase chiefly
due to lack of response (n = 23) or adverse effects (n = 15). One hundred
eleven patients (72%) entered into the long-term phase. After 6, 12, 18 and
27 months of treatment, the probability of no recurrence of SVA was 61 %,
54%, 51 % and 36%, respectively. Also at a mean duration of therapy with
d,l-sotalol of 8.7 months and compared to baseline. the percent of patients
having palpitations or dizziness decreased from 92% to 74% (p = 0.005) and
from 56% to 40% (p = 0.0231, respectively. During long-term treatment, 48
of 111 (43%) patients discontinued d,l-sota/ol chiefly because of loss of ef-
ficacy (n = 30) or adverse effects (n = 9). The probability of continuing with
d,l-sotalol at 6, 12, 18 and 27 months was 69%, 58%, 56% and 49%, respec-
tively. New clinical events attributable to d,l-sotalol were mostly cardiovas-
cular (palpitations, bradycardia, chest pain and dyspnea) or central nervous
effects (fatigue, dizziness and sleep problems). Only 4 (2.6%) of the 154 pa-
tients experienced proarrhythmia, of which 3 (1.9%) episodes were torsades
de pointes: 2 in the acute phase and 1 in the long-term phase. None of these
episodes were fatal.
Conclusion: Estimates of arrhythmia and symptom recurrence in addition
to safety data suggest that d,l-sotalol is efficacious in the treatment of drug-
refractory SVA.
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Role of Biplane Transesophageal
Echocardiography In Assessing Severity of Aortic
Stenosis: Planimetry vs. Continuity Equation
Miguel Zabalgoltia, Avanindra Jain, Rex Outtrim, Edward Sako, Robert A. O'Rourke.
The University of Texas Health Science Center at San Antonio, San Antonio, TX
Ultra-low frequency heart rate variability can predict progression to valve
surgery or cardiac death in patients with mitral regurgitation, but its prog-
nostic value in patients with chronic pure aortic regurgitation has not been
defined. We examined heart rate variability in 46 asymptomatic or minimally
symptomatic patients with chronic severe aortic regurgitation and no evi-
dent coronary disease, who underwent ambulatory electrocardiography as
part of a prospective study of the natural history of regurgitant valvular dis-
eases. At entry, all patients were in sinus rhythm, and were NYHA functional
class I or early II, with left ventricular ejection fraction :;:45%, left ventricular
dimension in diastole (LVIDd) :;:5.5 cm in females, LVIDd :;:5.9 cm in males.
Endpoints were progression to aortic valve replacement (n = 19) or cardiac
death (n = 1). A measure of ultra-low frequency heart rate variability, SDANN,
was calculated as the standard deviation of the 5 minute mean RR intervals
over 24 hours. Based on a median SDANN of 144 msec as a partition value,
event-free survival in patients with SDANN <144 msec (n = 23) was com-
pared to that in patients with SDANN :;:144 msec (n = 23) using the log rank
test, as shown in the figure. The average annual risk of endpoint events was
10.2% for SDANN <144 msec and 2.6% for SDANN :;:144 msec (p = 0.003).
Conclusion: Ultra-low frequency heart rate variability measured as SDANN
strongly concentrates risk of progression to valve surgery or cardiac death
in asymptomatic and minimally symptomatic patients with chronic pure aor-
tic regurgitation.
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Accurate calculation of aortic valve area (AVA) by the continuity equation
(CE): A1 . Vl N2' relies on an optimal 2D imaging of Al (LV outflow tract
[LVOTI diameter/2 . 1r. To evaluate: 1) whether transesophageal echo (TIE)-
LVOT can be utilized as an alternative to transthoracic echo (TIE), and 2) to
compare the AVA measured by direct TEE planimetry (PL) in the same popu-
lation, 48 pts with suspected aortic stenosis (AS) underwent TIE simultane-
ously (24 pts) or within 7 days (24 pts) prior to catheterization (CATH). When
simultaneously, Doppler signals were superimposed to CATH pressure trac-
ings. Biplane TEE was done within 48-hrs of CATH. AVA by PL, Doppler-
derived maximal instantaneous gradient (MIG), mean gradient (mG) and AVA
using LVOT area from TTE and from TEE were compared with CATH. Results:
TTE-LVOTwas suboptimal in 9 (19%) pts, and in none byTEE. AVA by PL was
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The effect of facilitation on AV nodal function was studied in twelve patients
before and after radiofrequency ablation (RFA) of the slow pathway. AV nodal
recovery time (H 1A2 or H2A3) was plotted against AV nodal conduction time(A2H2 or A3H3) for test intervals from control and facilitation protocols re-
spectively (see figure). The mean Al A2 for the facilitation protocol was 363 ±
15 ms. The minimal recovery time (RT), functional refractory period (FRP) and
conduction time (CT) of both the fast and slow pathways were determined.
The effect of facilitation on CT was assessed at the minimal RT obtained
during control testing. Results:
